Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 11:13:961805.
doi: 10.3389/fimmu.2022.961805. eCollection 2022.

Clinical cancer immunotherapy: Current progress and prospects

Chenglong Liu  1 , Mengxuan Yang  1 , Daizhou Zhang  2 , Ming Chen  3   4 , Di Zhu  1   2   5
Affiliations
Review

Clinical cancer immunotherapy: Current progress and prospects

Chenglong Liu et al. Front Immunol. .

Abstract

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and robust therapeutic potential in clinical practice. It can significantly improve progression-free survival and overall survival. Following surgery, radiotherapy, chemotherapy, and targeted therapy, cancer treatment has now entered the age of immunotherapy. Although cancer immunotherapy has shown remarkable efficacy, it also suffers from limitations such as irAEs, cytokine storm, low response rate, etc. In this review, we discuss the basic classification, research progress, and limitations of cancer immunotherapy. Besides, by combining cancer immunotherapy resistance mechanism with analysis of combination therapy, we give our insights into the development of new anticancer immunotherapy strategies.

Keywords: CAR-T; cancer vaccines; immune checkpoint inhibitors; immunotherapy; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Cancer immunotherapy methods, including monoclonal antibodies (mAbs), small molecule drugs, adoptive cell therapy, oncolytic virus, and cancer vaccines. CAR, chimeric antigen receptor. CXCR, C-X-C motif chemokine receptor. TAAs, tumor-associated antigens. ADCC, antibody-dependent cell-mediated cytotoxicity. PD-1, programmed death-1. PD-L1, programmed death-ligand 1. CTLA-4, cytotoxic T-lymphocyte-associated protein 4.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest (2007) 117:1137–46. doi: 10.1172/JCI31405 - DOI - PMC - PubMed
    1. Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, et al. . Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer (2021) 9:e002459. doi: 10.1136/jitc-2021-002459 - DOI - PMC - PubMed
    1. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. . Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell (2015) 162:1229–41. doi: 10.1016/j.cell.2015.08.016 - DOI - PMC - PubMed
    1. Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell (2018) 175:313–26. doi: 10.1016/j.cell.2018.09.035 - DOI - PMC - PubMed
    1. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest (2015) 125:3335–7. doi: 10.1172/JCI83871 - DOI - PMC - PubMed

Publication types

Substances